Hematopoietic cancer and angiogenesis

Stem Cells and Development

Volumn 13, Issue 5, 2004, Pages 484-495

  Ribatti, Domenico ^a   Scavelli, Claudio ^a   Roccaro, Aldo M ^a   Crivellato, Enrico ^b   Nico, Beatrice ^a   Vacca, Angelo ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; DEHYDRODIDEMNIN B; ENDOSTATIN; FIBROBLAST GROWTH FACTOR 2; GELATINASE A; GELATINASE B; GW 654652; IMMUNOMODULATING AGENT; MESSENGER RNA; PROTEIN TYROSINE KINASE INHIBITOR; REVEMID; THALIDOMIDE DERIVATIVE; VASCULOTROPIN; VATALANIB;

ACUTE LYMPHOCYTIC LEUKEMIA; ANGIOGENESIS; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; DISEASE COURSE; HEMATOLOGIC MALIGNANCY; HUMAN; MULTIPLE MYELOMA; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; REVIEW; STROMA CELL;

ANGIOGENESIS INHIBITORS; CELL PROLIFERATION; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; HEMATOLOGIC NEOPLASMS; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LYMPHOMA; MATRIX METALLOPROTEINASES; MODELS, BIOLOGICAL; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC; STROMAL CELLS; THALIDOMIDE;

EID: 8144224970     PISSN: 15473287     EISSN: None     Source Type: Journal    
DOI: 10.1089/scd.2004.13.484     Document Type: Review

References (91)

1. Ribatti D, A Vacca and F Dammacco. (1999). The role of the vascular phase in solid tumor growth: a historical review. Neoplasia 1:293-302.
2. Folkman J (1995). Clinical applications of research on angiogenesis. N Engl J Med 333:1757-1763.
3. Pezzella F, U Pastorino, E Tagliabue, S Andreola, G Sozzi, G Gasparini, S Menard, KC Gatter, AL Harris, S Fox, M Buyse, S Pilotti, M Pierotti and F Rilke. (1997). Non-small-lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am J Pathol 151:1417-1423.
4. Maniotis AJ, R Folberg, A Hess, EA Seftor, LMG Gardner, J Peier, JM Trent, PS Meltzer and MJC Hendrix. (1999). Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 155:739-752.
5. Folkman J. (1990). What is the evidence that tumors are angiogenesis-dependent? J Natl Cancer Inst 82:4-6.
6. Ribatti D, A Vacca, F Dammacco and D English. (2003). Angiogenesis and anti-angiogenesis in hematological malignancies. J Hematother Stem Cell Res 12:11-22.
7. Perez-Atayde AR, SE Sallan, U Tedrow, S Connors, EN Allured and J Folkman. (1997). Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphocytic leukemia. Am J Pathol 150:815-821.
8. Pulè MA, C Gullmann, D Dennis, C Mc Mahon, M Jeffers and OP Smith. (2002). Increased angiogenesis in bone marrow of children with acute lymphoblastic leukaemia has not prognostic significance. Br J Haematol 118:991-998.
9. Aguayo AR, H Kantarajian, T Manshouri, C Gidel, E Estey, D Thomas, C Koller, Z Estov, S O'Brien, M Keating, M Freing, E Freireich and M Albitar. (2000). Angiogenesis in acute and chronic leukemia and myelodysplastic syndromes. Blood 96:2240-2245.
10. Molica S, C Vitelli, D Levato, GM Gandolfo and V Liso. (1999). Increased serum levels of vascular endothelial growth factor predict risk of progression in early B-cell chronic lymphocytic leukemia. Br J Haematol 107:605-610.
11. Chen H, AT Treeweeke, DC West, KJ Till, JC Cawley, M Zuzel and CH Toth. (2000). In vitro and in vivo production of vascular endothelial growth factor in chronic lymphocytic leukemia cells. Blood 96:3181-3817.
12. Kini AR, NE Kay and LC Peterson. (2000). Increased bone marrow angiogenesis in B-cell chronic lymphocytic leukemia. Blood 100:3344-3351.
13. Duensing S and J Atzpodien. (1995). Increased intracellular and plasma levels of basic fibroblast growth factor in B-cell chronic lymphocytic leukemia cells. Blood 85:1978-1980.
14. Menzel T, Z Rahman, E Calleja, K White, EL Wilson, R Wieder and J Gabrilove. (1996). Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabine. Blood 87:1056-1063.
15. Bellamy WT, L Richter, Y Frutiger and TM Grogan. (1999). Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 59:728-733.
16. Dias S, K Hattori, Z Zhu, B Heissig, M Chay, W Lane, Y Wu, A Chadbrun, E Hyjek, M Gill, DJ Hicklin, L Witte, MA Moore and S Raffi. (2000). Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest 106:511-521.
17. Konig A, T Menzel, S Lynes, L Wrazel, A Rosen, A Al-Katib, E Raveche and JL Gabrilove. (1997). Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B-cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis. Leukemia 11:258-265.
18. Lundberg LG, P Lerner, R Sundelin, R Rogres, J Folkman and J Palmblad. (2000). Bone marrow in polycythemia vera, chronic myelocytic leukemia and myelofibrosis has an increased vascularity. Am J Pathol 157:15-19.
19. Molica S, A Vacca, D Ribatti, A Cuneo, F Cavazzini, D Levato, G Vitelli, L Tucci, AM Roccaro and F Dammacco. (2002). Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia. Blood 100:3344-3351.
20. Vacca A, D Ribatti, L Roncali, G Ranieri, G Serio, F Silvestris and F Dammacco. (1994). Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 87:503-508.
21. Vacca A, D Ribatti, M Presta, M Minischetti, M Iurlaro, R Ria, A Albini, F Bussolino and F Dammacco. (1999). Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 93:3064-3073.
22. Di Raimondo FD, MP Azzaro, GA Palumbo, S Bagnato, G Giustolisi, PM Floridia, G Sortino and R Giustolisi. (2000). Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood. Haematologica 85:800-805.
23. Iwasaki T, T Hamano, T Ogata, N Hashimoto, M Kitano and E Kakishita. (2002). Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma. Br J Haematol 116:796-802.
24. Soubrier M, J Dubost, AF Serre, JM Ristori, B Sauvezie, P Cathebras, JC Piette, A Chapman, FJ Authier and RK Gherardi. (1997). Growth factors in POEMS syndrome: evidence for a marked increase in circulating vascular endothelial growth factor. Arthrit Rheum 40:786-787.
25. Vacca A, R Ria, D Ribatti, F Semeraro, V Djonov, F Di Raimondo and F Dammacco. (2003). A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. Haematologica 88:176-185.
26. Asosingh K, H De Raeve, E Menu, I van Riet, E Van Marck, B van Camp and K Vanderkerken. (2004). Angiogenic switch during 5T2MM murine myeloma tumorigenesis: role of CD45 heterogeneity. Blood 103:3131-3137.
27. Ribatti D, A Vacca, B Nico, M Fanelli, L Roncali and F Dammacco. (1996). Angiogenesis spectrum in the stroma of B-cell non-Hodgkin's lymphomas. An immunohistochemical and ultrastructural study. Eur J Haematol 56:45-53.
28. Bellamy WT. (2001). Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies. Semin Oncol 28:551-559.
29. Stewart M, K Talks, R Leek, H Turley, F Pezzella, H Harris and K Gatter. (2002). Expression of angiogenic factors and hypoxia inducible factors HIF-1, HIF-2 and CAIX in non Hodgkin's lymphoma. Histopathology 40:253-260.
30. Salven P, L Teerenhovi and H Joensun. (1999). A high pretreatment serum basic fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin's lymphoma. Blood 94:3334-3339.
31. Bertolini F, M Paolucci, S Peccatori, S Cinieri, A Agazzi, PF Ferrucci, E Cocorocchio, A Goldhirsch and G Martinelli. (1999). Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. Br J Haematol 106:504-509.
32. Salven P, A Orpona, L Teerenhovi and H Joensun. (2000). Simulatenous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non Hodgkin's lymphoma: a single-institution study of 200 patients. Blood 96:3712-3718.
33. Foss HD, I Araujo, G Demel, H Klotzbach, M Hummel and H Stein. (1997). Expression of vascular endothelial growth factor in lymphomas and Castelman's disease. J Pathol 183:44-50.
34. Hazar B, Z Paydas, S Zorludemir, S Sahin and I Tuncer. (2003). Prognostic significance of microvessel density and vascular endothelial growth factor (VEGF) expression in non Hodgkin's lymphoma. Leuk Lymphoma 44:2089-2093.
35. Coussens LM and Z Werb. (1996). Matrix metalloproteinases and the development of cancer. Chem Biol 3:895-904.
36. Mignatti P and DB Rifkin. (1993). Biology and biochemistry of proteinases in tumor invasion. Physiol Review 73:161-195.
37. Vacca A, D Ribatti, M Iurlaro, A Albini, M Minischetti, F Bussolino, A Pellegrino, R Ria, M Rusnati, M Presta, V Vincenti, MG Persico and F Dammacco. (1998). Human lymphoblastoid cells produce extracellular matrix-degrading enzymes and induce endothelial cell proliferation, migration, morphogenesis and angiogenesis. Int J Clin Lab Res 28:55-68.
38. Barilleè S, C Aknoundi, M Collette, MP Mellerin, MJ Rapp, JL Harrousseau, R Bataille and M Amiot. (1997). Metalloproteinases in multiple myeloma: production of matrix metalloproteinase 9 (MMP-9), activation of pro-MMP-2, and induction of MMP-1 by myeloma cells. Blood 90:1649-1655.
39. Hayashibara T, Y Yamada, Y Onimaru, C Tsutsumi, S Nakayama, N Mori, T Miyanishi, S Kamihira, M Tomonaga and T Maita. (2002). Matrix metalloproteinase-9 and vascular endothelial growth factor: a possible link in adult T-cell leukemia cell invasion. Br J Haematol 116:94-102.
40. Lin LI, DT Lin, CJ Chang, CY Lee, JL Tang and HF Tien. (2002). Marrow matrix metalloproteinases (MMPs) and tissue inhibitors of MMP in acute leukaemia: potential role of MMP-9 as a surrogate marker to monitor leukaemic status in patients with acute myelogenous leukaemia. Br J Haematol 117:835-841.
41. Bauovois B, J Dumont, C Mathiot and JP Kolb. (2002). Production of matrix metalloproteinase-9 in early C-CLL: suppression by interferons. Leukemia 16:791-798.
42. Kay NE, ND Bone, RC Tschumper, KH Howell, SM Geyer, GW Dewald, CA Hanson and DF Jelinek. (2002). B-CLL cells are capable of synthesis and secretion of both pro-and anti-angiogenic molecules. Leukemia 16:911-916.
43. Kamiguti AS, ES Lee, KJ Till, RJ Harris, MA Gleen, K Lin, HJ Chen, M Zuzel and JC Cawley. (2004). The role of matrix metalloproteinase 9 in the pathogenesis of chronic lymphocytic leukaemia. Br J Haematol 125:128-140.
44. Taichman RS, MJ Reilly and SG Emerson. (1996). Human ostoblasts support human hematopoietic progenitor cells in in vitro bone marrow cultures. Blood 88:518-524.
45. Dankbar B, T Padro, R Leo, B Feldmann, M Kropff, RM Mesters, H Serve, WE Berdel and J Kienast. (2000). Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 95:2630-2636.
46. Fiedler W, V Graeven, S Ergun, S Verago, N Kilic, M Stockschladeer and DK Hossfeld. (1997). Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood 89:1870-1875.
47. Solanilla A, A Elandaloussi, C Grosset, P Duchez, MD Mossalayi, FX Mahon, J Reiffers, G Marit and J Ripoche. (2000). Differential effect of interferon alpha on chronic myelogenous leukaemia and normal haemopoietic progenitors in a stromal cell co-culture context: role of the flt3 ligand. Brit J Haematol 109:382-387.
48. Allouche AR, F Bayard, S Clamens, G Fillolla, P Sie and F Amalric. (1995). Expression of basic fibroblast growth factor (bFGF) and FGF-receptors in human leukemic cells. Leukemia 9:77-86.
49. Fusetti L, G Pruneri, A Gobbi, C Rabascio, N Carboni, F Peccatori, G Martinelli and F Bertolini. (2000). Human myeloid and lymphoid malignancies in the non-obese diabetic/severe combined immunodeficiency mouse model: frequency of apoptotic cells in solid tumors and efficiency and speed of engrafment correlate with vascular endothelial growth factor production. Cancer Res 60:2527-2534.
50. Klein B, X Zhang and Z Lu. (1995). Interleukin-6 in human multiple myeloma. Blood 85:863-872.
51. Bataille R and JL Harousseau. (1997). Multiple myeloma. New Engl J Med 336:1657-1664.
52. Deckers MM, M Karperien, C van der Bent, T Yamashita, SE Papapoulos and CW Lowik. (2000). Expression of vascular endothelial growth factors and their receptors during osteoblast differentiation. Endocrinology 141:1667-1674.
53. Nakagawa M, T Kaneda, T Arawaka, S Morita, T Sato, T Yomada, K Kanada, M Kumegawa and Y Hakeda. (2000). Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts. FEBS Lett 473:161-164.
54. Bellamy WT, L Richter, D Sirjani, C Roxas, B Glinsmann-Gibson, Y Frutiger, TM Grogan and AF List. (2001). Vascular endothelial growth factor (VEGF) is an autocrine promoter of abnormal localized immature precursors (ALIP) and leukemia progenitor formation in myelodysplastic syndromes. Blood 97:1427-1434.
55. Ribatti D, A Vacca, B Nico, F Quondamatteo, R Ria, M Minischetti, A Marzullo, R Herken, L Roncali and F Dammacco. (1999). Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma. Br J Cancer 79:451-455.
56. Ribatti D, B Nico, A Vacca, A Marzullo, N Calvi, L Roncali and F Dammacco. (1998). Do mast cells help to induce angiogenesis in B-cell non-Hodgkin's lymphomas? Br J Cancer 77:1900-1906.
57. Ribatti D, A Vacca, A Marzullo, B Nico, R Ria, L Roncali and F Dammacco. (2000). Angiogenesis and mast cell density with tryptase activity increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. Int J Cancer 85:171-175.
58. Fukushima N, H Sato, M Sano and O Tokunaga. (2001). Angiogenesis and mast cells in non Hodgkin's lymphoma: a strong correlation in angioimmunoblastic T-cell lymphoma. Leuk Lymphoma 42:709-720.
59. Ribatti D, S Molica, A Vacca, B Nico, E Crivellato, AM Roccaro and F Dammacco. (2003). Tryptase-positive mast cells correlate positively with bone marrow angiogenesis in B-cell chronic lymphocytic leukemia. Leukemia 17:1428-1430.
60. Vacca A, D Ribatti, L Ruco, F Giacchetta, B Nico, F Quondamatteo, R Ria, M Iurlaro and F Dammacco. (1999). Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphoma. Br J Cancer 79:965-970.
61. Singhal S, J Metha, R Desijan, D Ayers, P Robertson, P Eddleman, N Munshi, E Anaissie, C Wilson, M Dhodhapakar, J Zeldis and B Barlogie. (1999). Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565-1571.
62. Richardson P, T Hideshima and K Anderson. (2002). Thalidomide: emerging role in cancer medicine. Annu Rev Med 53:629-657.
63. Rajkumar SV, MA Gertz, MQ Lacy, A Dispenzieri, G Fonseca, SM Geyer, N Iturria, S Kumar, JA Lust, RA Kyle, PR Greipp and TE Witzig. (2003). Thalidomide as initial therapy for early stage myeloma. Leukemia 17:775-779.
64. Moehler TM, K Neben, A Benner, G Egerer, F Krosnigi, AD Ho and H Goldschmidt. (2001). Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. Blood 98:3846-3858.
65. Kropff MH, N Lang, G Bisping, N Domine, G Inning, M Hentrich, M Mitterer, T Sudhoff, R Fenk, C Straka, A Heinecke, CM Koch, H Ostermann, WE Berdel and J Kienost. (2003). Hyperfractioned cyclophosphamide in combination with pulsed dexamethasone and thalidomide (Hyper CTD) in primary refractory or relapsed multiple myeloma. Br J Haematol 122:607-616.
66. Dredge K, JB Marriott, CE Macdonald, HV Mann, R Chen, GW Muller, D Stirling and AG Dalgleish. (2002). Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer 87:1166-1172.
67. Hideshima T, D Chauhan, Y Shima, N Raje, FE Davies, YT Tai, SP Treon, B Lin, RL Schlossmann, P Richardson, G Muller, DI Stirling and KC Anderson. (2000). Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 96:2943-2950.
68. Hideshima T, P Richardson, D Chauhan, VJ Palombella, PJ Elliott, J Adams and KC Anderson. (2001). The proteasome inhibitor PS 341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61:3071-3076.
69. Rousselot P, S Labaume, JP Marolleau, J Larghero, MH Noguera, JC Brouet and JP Fermand. (1999). Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients. Cancer Res 59:1041-1048.
70. Park WH, JG Seol, ES Kim, JM Hyum, CW Jung, CC Lee, BH Kim and YY Lee. (2000). Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res 60:3065-3071.
71. Richardson PG, RL Schlossman, E Weller, T Hideshima, C Mitsiades, F Davies, R Leblanc, LP Catley, D Doss, K Kelly, M Mkenney, J Mechlowicz, A Freeman, R Deocampo, R Rich, JJ Ryoo, D Chauhan, K Balinski, J Zelois J and KC Anderson. (2002). Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100:3063-3067.
72. Gupta D, SP Treon, Y Shima, T Hideshima, K Podar, YT Tai, B Lin, S Lentzsch, FE Davies, D Chauhan, RL Schlossman, P Richardson, P Ralph, L Wu, F Dayvandi, G Muller, DI Stirling and KC Anderson. (2001). Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 15:1950-1961.
73. Raza A, P Meyer, D Dutt, F Zorat, L Lisak, F Nascimben, M duRandt, C Kaspar, C Goldberg, J Loew, S Dar, S Gezer, P Venugopal and J Zeldis. (2001). Thalidomide produces transfusion independence in long-standing refractory anemia of patients with myelodysplastic syndormes. Blood 98:958-965.
74. Strupp C, U Germing, M Sivado, E Misgeld, R Haas and N Gottermann. (2002). Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia 16:1-6.
75. Strupp C, B Hildebrandt, U Germing, R Haas and N Gottermann. (2003). Cytogenetic response to thalidomide treatment in three patients with myelodysplastic syndrome. Leukemia 17:1200-1202.
76. Strupp C, M Aivado, U Germing, N Gottermann and R Haas. (2002). Angioimmunoblastic lymphadenopathy (AIDL) may respond to thalidomide treatment: two case report. Leuk. Lymphoma 43:133-137.
77. Wilson EA, S Jobanputra, R Jackson, AN Parker and IG McQuaker. (2002). Response to thalidomide in chemotherapy-resistant mantle cell lymphoma: a case-report. Br J Haematol 119:128-130.
78. Steins MB, T Padro, R Biecker, S Ruiz, M Kropff, J Kienast, T Kessler, T Buechner, WE Berdel and RM Mesters. (2002). Efficacy and safety of thalidomide in patients with acute myeloid leukemia. Blood 99:834-839.
79. Vacca A, M Iurlaro, D Ribatti, M Minischetti, B Nico, R Ria, A Pellegrino and F Dammacco. (1999). Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood 94:4143-4155.
80. Kerbel KS, A Viloria-Petit, G Klement and J Rak. (2000). 'Accidental' anti-angiogenic drugs: anti-oncogene directed signal transduction inhibitors and conventional chemoterapeutic agents as examples. Eur J Cancer 36:1248-1257.
81. Klement G, S Baruchel, J Rak, S Man, K Clark, DJ Hicklin, P Bohlen and RS Kerbel. (2000). Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105:R15-R24.
82. Brodwer T, CE Butterfield, BM Kraling, B Shi, B Marshall, M O'Reilly and J Folkman. (2001). Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60:1878-1886.
83. Scappaticci FA, R Smith, A Pathak, D Schloss, B Lum, Y Cao, F Johnson, EG Engleman and GP Nolan. (2001). Combination angiostatin and endostatin gene transfer induces synergistic antiangiogenic activity in vitro and antitumor efficacy in leukemia and solid tumors in mice. Mol Therapy 3:186-196.
84. Bertolini F, L Fugetti, P Mancuso, A Gobbi, C Corsini, PF Ferrucci, G Martinelli and G Pruned. (2000). Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin's lymphoma. Blood 96:282-287.
85. Talks KL and AL Harris. (2000). Current status of antiangiogenic factors. Br J Haematol 109:477-489.
86. Presta LG, H Chen, SJ O'Connors, V Chisholm, YG Meng, L Krummen, M Winkler and N Ferrara. (1997). Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57:5493-5499.
87. Lin B, K Podar, D Gupta, YT Tay, S Li, E Weller, T Hideshima, S Lentzsch, F Davies, C Li, E Weisberg, RL Schlossman, PG Richardson, JD Griffin, J Wood, NC Munschi and KC Anderson. (2002). The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK 787/ZK 222584 inhibits growth and migration of multiple myeloma kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res 62:5019-5026.
88. Podar K, LP Catley, YT Tai, R Shringapure, P Carvalho, T Hayashi, R Burger, RL Schlossman, PG Richardson, LN Pandite, R Kumar, T Hideshima, D Chauhan and KC Anderson. (2004). GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment. Blood 103:3474-3479.
89. Quesada JR, EM Hersh, J Manning, J Keuben, M Keating, E Schnipper, L Itri and JU Guterman. (1986). Treatment of hairy cell leukemia with recombinant alpha interferon. Blood 68:493-497.
90. Di Raimondo F, E Fichera, MP Azzaro, F Stagno, GA Palumbo and R Giustolisi. (2000) Low serum levels of vascular endothelial growth factor (VEGF) and hepatocyte growth-factor (HGF) in IFN-treated chronic myeloid leukemia (CML) patients (abstract 4825). Blood 96 (suppl 1):253b.
91. Broggini M, SV Marchini, E Galliera, P Borsotti, G Taraboletti, E Erba, M Sironi, J Jimeno, GT Faircloth, R Giavazzi and M D'Incalci. (2003). Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGE-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4. Leukemia 17:52-59.